An ATP competitive RIPK1 kinase inhibitor GSK2982772 is now in clinical phase II for treating ulcerative colitis, and another RIPK1 inhibitor DNL758 has been initiated for phase II study in cutaneous lupus erythematosus patients. The gene discussed is RIPK1; the disease is cutaneous lupus erythematosus.